Apoptosis, proliferation and NF-κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: Amplification of Fas-mediated apoptosis by tumor necrosis factor

European Journal of Haematology

Volumn 63, Issue 5, 1999, Pages 345-353

  Børset, Magne ^a,b   Hjorth Hansen, Henrik ^a   Johnsen, Ann Charlotte ^a   Seidel, Carina ^a   Waage, Anders ^a   Espevik, Terje ^a   Sundan, Anders ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Fas; Multiple myeloma; NF B; OH 2; Tumor necrosis factor

Indexed keywords

CASPASE INHIBITOR; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INDUCTION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

EID: 0032757670     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01138.x     Document Type: Article

References (52)

1. 1. NAGATA K, TANAKA Y, ODA S, YAMASHITA U, ETO S. Interleukin 1 autocrine growth system in human multiple myeloma. Jpn J Clin Oncol 1991;21:22-29.
2. 2. ANDERSON KC, JONES RM, MORIMOTO C, LEAVITT P, BARUT BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989;73:1915-1924.
3. 3. SAWAMURA M, MURAKAMI H, TAMURA J, et al. Tumour necrosis factor-alpha and interleukin 4 promote the differentiation of myeloma cell precursors in multiple myeloma. Br J Haematol 1994;88:17-23.
4. 4. LU ZY, ZHANG XG, RODRIGUEZ C, et al. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521-2527.
5. 5. GU ZJ, COSTES V, LU ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996;88:3972-3986.
6. 6. JOURDAN M, ZHANG XG, PORTIER M, BOIRON JM, BATAILLE R, KLEIN B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 1991;147:4402-4407.
7. 7. BORSET M, WAAGE A, BREKKE OL, HELSETH E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994;53:31-37.
8. 8. HATA H, MATSUZAKI H, TAKATSUKI K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Haematol 1990;83:133-136. 1994;53:31-37.
9. 8. HATA H, MATSUZAKI H, TAKATSUKI K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Haematol 1990;83:133-136. 1994;53:31-37.
10. 9. HJORTH-HANSEN H, WAAGE A, BORSET M. IL-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. Br J Haematol 1999;106:28-34.
11. 10. BROSH N, STERNBERG D, HONIGWACHS-SHA'ANANI J, et al. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stroma-derived activin A. J Biol Chem 1995; 270:29594-29600.
12. 11. PORTIER M, ZHANG XG, CARON E, LU ZY, BATAILLE, R, KLEIN B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993;81:3076-3082.
13. 12. HATA H, MATSUZAKI H, TAKEYA M, et al. Expression of Fas/ Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995;86:1939-1945.
14. 13. NAGATA S. Apoptosis by death factor. Cell 1997;88:355-365.
15. 14. ENARI M, SAKAHIRA H, YOKOYAMA H, OKAWA K, IWAMATSU A, NAGATA S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:96-99.
16. 15. MAPARA MY, BARGOU R, ZUGCK C, et al. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993;23:702-708.
17. 16. AGGARWAL, BB, SINGH S, LAPUSHIN R, TOTPAL K. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995;364:5-8.
18. 17. ALDERSON MR, ARMITAGE RJ, MARASKOVSKY E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993;178:2231-2235.
19. 18. PONTON A, CLEMENT MV, STAMENKOVIC I. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J Biol Chem 1996;271:8991-8995.
20. 19. SCHULE-OSTHOFF K, KRAMMER PH, DROGE W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 1994;13:4587-4596.
21. 20. RAVI R, BEDI A, FICHS EJ. CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB. Cancer Res 1998; 58:882-886.
22. 21. DANIEI PT, KRAMMER PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994;152:5624-5632.
23. 22. WESTENDORF JJ, LAMMERT JM, JELINEK DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995;85:3566-3576.
24. 23. EGLE A, VILLUNGER A, MARSCHITZ I, et al. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br J Haematol 1997;97:418-428.
25. 24. LANDOWSKI TH, QU N, BUYUKSAL I, PAINTER JS, DALTON WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997;90:4266-4270.
26. 25. MANDAL M, MAGGIRWAR SB, SHARMA N, KAUFMANN SH, SUN SC, KUMAR R. Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. J Biol Chem 1996;271:30354-30359.
27. 26. JAATTELA M, BENEDICT M, TEWARI M, SHAYMAN JA, DIXIT VM. Bcl-X and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 1995;10:2297-2305.
28. 27. WANG D, FREEMAN GJ, LEVINE H, RITZ J, ROBERTSON MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997;97:409-417.
29. 28. BORSET M, MEDVEDJEV AE, SUNDAN A, ESPEVIK T. The role of the two TNF receptors in proliferation, NF-kappaB activation and discrimination between TNF and LTalpha signaling in the human myeloma cell line OH-2. Cytokine 1996;8:430-438.
30. 29. NILSSON K, BENNICH H, JOHANSSON SGO, PONTEN J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970;7:477-489.
31. 30. MOORE GE, KITAMURA H. Cell line derived from patient with myeloma. N Y State J Med 1968;68:2054-2060.
32. 31. JACKSON N, LOWE J, BALL J, et al. Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin Exp Immunol 1989;75:93-99.
33. 32. ESPEVIK T, BROCKHAUS M, LOETSCHER H, NONSTAD U, SHALABY R. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med 1990;171:415-426.
34. 33. BROCKHAUS M, SCHOENFELD HJ, SCHLAEGER EJ, HUNZIKER W, LESSLAUER W, LOETSCHER H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:3127-3131.
35. 34. LAEGREID A, MEDVEDEV A, NONSTAD U, et al. Tumor necrosis factor receptor p75 mediates cell-specific activation of nuclear factor kappa B and induction of human cytomegalovirus enhancer. J Biol Chem 1994;269:7785-7791.
36. 35. DIGNAM JD, LEBOVITZ RM, ROEDER RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-1489.
37. 36. LE J, REIS LF, VILCEK J. Tumor necrosis factor and interleukin 1 can act as essential growth factors in a murine plasmacytoma line. Lymphokine Res 1988;7:99-106.
38. 37. SHIMIZU S, YOSHIOKA R, HIROSE Y, SUGAI S, TACHIBANA J, KONDA S. Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989;169:339-344.
39. 38. THAVASU PW, GANJOO RK, MAIDMENT SA, et al. Multiple myeloma: an immunoclinical study of disease and response to treatment. Hematol Oncol 1995;13:69-82.
40. 39. NACHBAUR DM, HEROLD M, MANESCHG A, HUBER H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991; 62:54-58.
41. 40. BLADE J, FILELLA X, MONTONO S, et al. Clinical relevance of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) serum levels in monoclonal gammopathy of undetermined significance (MGUS). Blood 1997;90:351a (Abstract).
42. 41. BORSET M, HELSETH E, WAAGE. A. Production of tumor necrosis factor alpha and beta by human myeloma cell lines. Bone Miner 1992;17(suppl.1):203.
43. 42. GARRETT IR, DURIE BG, NEDWIN GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526-532.
44. 43. PORTIER M, ZHANG XG, URSULE E, et al. Cytokine gene expression in human multiple myeloma. Br J Haematol 1993;85:514-520.
45. 44. VAN ANTWERP DJ, MARTIN SJ, KAFRI T, GREEN DR, VERMA IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996;274:787-789.
46. 45. LENS SM, TESSELAAR K, DEN DRIJVER BF, VAN OERS MH, VAN LIER RA. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 1996;156:507-514.
47. 46. OYAIZU N, MCCLOSKEY TW, THAN S, HU R, KALYANARAMAN VS, PAHWA S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 1994;84:2622-2631.
48. 47. SATO T, IRIE S, KITADA S, REED JC. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-415.
49. 48. IRMLER M, THOME M, HAHNE M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195.
50. 49. SPETS H, GEORGII-HEMMING P, SILJASON J, NILSSON K, JERNBERG-WIKLUNG H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon-in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998;92:2914-2923.
51. 50. EGLE A, VILLUNGER A, Kos M, et al. Modulation of Apo-1/ Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 1996; 26:3119-3126.
52. 51. WISSINK S, VAN HEERDE EC, VAN DER BURG B, VAN DER SAAG PT. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol 1998; 12:355-363.